Skip to main content
Erschienen in: Current Cardiology Reports 5/2015

01.05.2015 | Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease

verfasst von: Daniel I. Swerdlow, Aroon D. Hingorani, Steve E. Humphries

Erschienen in: Current Cardiology Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular disease encompasses several diverse pathological states that place a heavy burden on individual and population health. The aetiological basis of many cardiovascular disorders is not fully understood. Growing knowledge of the genetic architecture underlying coronary heart disease, stroke, cardiac arrhythmias and peripheral vascular disease has confirmed some suspected causal pathways in these conditions but also uncovered many previously unknown mechanisms. Here, we consider the contribution of genetics to the understanding of cardiovascular disease risk. We evaluate the utility and relevance of findings from genome-wide association studies and explore the role that Mendelian randomisation has to play in exploiting these. Mendelian randomisation permits robust causal inference in an area of research where this has been hampered by bias and confounding in observational studies. In doing so, it provides evidence for causal processes in cardiovascular disease that could represent novel targets for much-needed new drugs for disease prevention and treatment.
Literatur
1.
Zurück zum Zitat Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.CrossRefPubMed Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.CrossRefPubMed
2.
Zurück zum Zitat Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–82.CrossRefPubMedCentralPubMed Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–82.CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Fox KAA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4:e004425.CrossRefPubMedCentralPubMed Fox KAA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4:e004425.CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat Brotman DJ, Walker E, Lauer MS, O’Brien RG. In search of fewer independent risk factors. Arch Intern Med. 2005;165:138–45.CrossRefPubMed Brotman DJ, Walker E, Lauer MS, O’Brien RG. In search of fewer independent risk factors. Arch Intern Med. 2005;165:138–45.CrossRefPubMed
5.
Zurück zum Zitat Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.CrossRefPubMed Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.CrossRefPubMed
6.
Zurück zum Zitat Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383:1899–911.CrossRefPubMedCentralPubMed Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383:1899–911.CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.CrossRefPubMed Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.CrossRefPubMed
8.
Zurück zum Zitat Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.CrossRefPubMedCentralPubMed Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Emerging Risk Factors Collaboration, Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.CrossRef Emerging Risk Factors Collaboration, Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.CrossRef
10.
Zurück zum Zitat Fruchart J-C, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.CrossRefPubMedCentralPubMed Fruchart J-C, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.CrossRefPubMedCentralPubMed
11.••
Zurück zum Zitat Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90a. Recent European guidance on the clinical management of familial hypercholesterolaemia.CrossRefPubMedCentralPubMed Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90a. Recent European guidance on the clinical management of familial hypercholesterolaemia.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Futema M, Plagnol V, Li K, Whittall RA, Neil HAW, Seed M, et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet. 2014;51:537–44.CrossRefPubMedCentralPubMed Futema M, Plagnol V, Li K, Whittall RA, Neil HAW, Seed M, et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet. 2014;51:537–44.CrossRefPubMedCentralPubMed
13.••
Zurück zum Zitat Fouchier SW, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res. 2014;115:552–5. Report of a novel locus responsible for causing familial hypercholesterolaemia.CrossRefPubMed Fouchier SW, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res. 2014;115:552–5. Report of a novel locus responsible for causing familial hypercholesterolaemia.CrossRefPubMed
14.••
Zurück zum Zitat Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang Z-Z, et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014;94:233–45. Demonstration of the use of whole-exome sequencing for investigating genetic determinants of atherosclerosis and coronary heart disease.CrossRefPubMedCentralPubMed Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang Z-Z, et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014;94:233–45. Demonstration of the use of whole-exome sequencing for investigating genetic determinants of atherosclerosis and coronary heart disease.CrossRefPubMedCentralPubMed
15.••
Zurück zum Zitat McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9:356–69. A guide to the development, application and utility of genome-wide association studies.CrossRefPubMed McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9:356–69. A guide to the development, application and utility of genome-wide association studies.CrossRefPubMed
16.
Zurück zum Zitat Hindorff LA, Junkins HA, Hall P, Mehta JP, Manolio TA. A catalog of published genome-wide association studies [Internet]. Cat Publ Genome-Wide Assoc Stud. [cited 2011 Jun 30]. Available from: www.genome.gov/gwastudies. Hindorff LA, Junkins HA, Hall P, Mehta JP, Manolio TA. A catalog of published genome-wide association studies [Internet]. Cat Publ Genome-Wide Assoc Stud. [cited 2011 Jun 30]. Available from: www.​genome.​gov/​gwastudies.
17.••
Zurück zum Zitat Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012;45:25–33. The largest meta-analysis of genome-wide association studies of coronary heart disease published to date.CrossRefPubMed Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012;45:25–33. The largest meta-analysis of genome-wide association studies of coronary heart disease published to date.CrossRefPubMed
18.
Zurück zum Zitat Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–9.CrossRefPubMed Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–9.CrossRefPubMed
19.
Zurück zum Zitat Arsenault BJ, Boekholdt SM, Dubé M-P, Rhéaume E, Wareham NJ, Khaw K-T, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7:304–10.CrossRefPubMed Arsenault BJ, Boekholdt SM, Dubé M-P, Rhéaume E, Wareham NJ, Khaw K-T, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7:304–10.CrossRefPubMed
20.
Zurück zum Zitat Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9.CrossRefPubMed Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9.CrossRefPubMed
21.
Zurück zum Zitat Tarasov KV, Sanna S, Scuteri A, Strait JB, Orrù M, Parsa A, et al. COL4A1 is associated with arterial stiffness by genome-wide association scan. Circ Cardiovasc Genet. 2009;2:151–8.CrossRefPubMedCentralPubMed Tarasov KV, Sanna S, Scuteri A, Strait JB, Orrù M, Parsa A, et al. COL4A1 is associated with arterial stiffness by genome-wide association scan. Circ Cardiovasc Genet. 2009;2:151–8.CrossRefPubMedCentralPubMed
22.••
Zurück zum Zitat Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann J, Shah T, Sofat R, et al. The interleukin-6 receptor as a potential target for coronary heart disease prevention: evaluation using Mendelian randomisation. Lancet. 2012;2012. A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Sarwar et al., below. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann J, Shah T, Sofat R, et al. The interleukin-6 receptor as a potential target for coronary heart disease prevention: evaluation using Mendelian randomisation. Lancet. 2012;2012. A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Sarwar et al., below.
23.••
Zurück zum Zitat Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–13. A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Swerdlow et al.CrossRefPubMed Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–13. A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Swerdlow et al.CrossRefPubMed
24.
Zurück zum Zitat Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274–83.CrossRefPubMed Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274–83.CrossRefPubMed
25.
26.
Zurück zum Zitat Peden JF, Hopewell JC, Saleheen D, Chambers JC, Hager J, Soranzo N, et al. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43:339–44.CrossRef Peden JF, Hopewell JC, Saleheen D, Chambers JC, Hager J, Soranzo N, et al. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43:339–44.CrossRef
27.
Zurück zum Zitat Johnson AD, Hwang S-J, Voorman A, Morrison A, Peloso GM, Hsu Y-H, et al. Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study. Circulation. 2013;127:799–810.CrossRefPubMedCentralPubMed Johnson AD, Hwang S-J, Voorman A, Morrison A, Peloso GM, Hsu Y-H, et al. Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study. Circulation. 2013;127:799–810.CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Roberts R, Stewart AFR. 9p21 and the genetic revolution for coronary artery disease. Clin Chem. 2012;58:104–12.CrossRefPubMed Roberts R, Stewart AFR. 9p21 and the genetic revolution for coronary artery disease. Clin Chem. 2012;58:104–12.CrossRefPubMed
29.••
Zurück zum Zitat International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9. A large genome-wide association study reporting common genetic determinants of blood pressure.CrossRef International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9. A large genome-wide association study reporting common genetic determinants of blood pressure.CrossRef
30.••
Zurück zum Zitat Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42:937–48. A very large genome-wide association study reporting novel genetic determinants of obesity-related traits.CrossRefPubMedCentralPubMed Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42:937–48. A very large genome-wide association study reporting novel genetic determinants of obesity-related traits.CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42:436–40.CrossRefPubMedCentralPubMed Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42:436–40.CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670–5.CrossRefPubMedCentralPubMed Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670–5.CrossRefPubMedCentralPubMed
33.
Zurück zum Zitat Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010;42:240–4.CrossRefPubMedCentralPubMed Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010;42:240–4.CrossRefPubMedCentralPubMed
34.
Zurück zum Zitat Butler AM, Yin X, Evans DS, Nalls MA, Smith EN, Tanaka T, et al. Novel loci associated with PR interval in a genome-wide association study of 10 African American cohorts. Circ Cardiovasc Genet. 2012;5:639–46.CrossRefPubMedCentralPubMed Butler AM, Yin X, Evans DS, Nalls MA, Smith EN, Tanaka T, et al. Novel loci associated with PR interval in a genome-wide association study of 10 African American cohorts. Circ Cardiovasc Genet. 2012;5:639–46.CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Sotoodehnia N, Isaacs A, de Bakker PIW, Dörr M, Newton-Cheh C, Nolte IM, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet. 2010;42:1068–76.CrossRefPubMedCentralPubMed Sotoodehnia N, Isaacs A, de Bakker PIW, Dörr M, Newton-Cheh C, Nolte IM, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet. 2010;42:1068–76.CrossRefPubMedCentralPubMed
36.
Zurück zum Zitat Ritchie MD, Denny JC, Zuvich RL, Crawford DC, Schildcrout JS, Bastarache L, et al. Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation. 2013;127:1377–85.CrossRefPubMedCentralPubMed Ritchie MD, Denny JC, Zuvich RL, Crawford DC, Schildcrout JS, Bastarache L, et al. Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation. 2013;127:1377–85.CrossRefPubMedCentralPubMed
37.
Zurück zum Zitat Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV, et al. Genome-wide association study of PR interval. Nat Genet. 2010;42:153–9.CrossRefPubMedCentralPubMed Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV, et al. Genome-wide association study of PR interval. Nat Genet. 2010;42:153–9.CrossRefPubMedCentralPubMed
38.
Zurück zum Zitat Chambers JC, Zhao J, Terracciano CMN, Bezzina CR, Zhang W, Kaba R, et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet. 2010;42:149–52.CrossRefPubMed Chambers JC, Zhao J, Terracciano CMN, Bezzina CR, Zhang W, Kaba R, et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet. 2010;42:149–52.CrossRefPubMed
39.
Zurück zum Zitat Holm H, Gudbjartsson DF, Arnar DO, Thorleifsson G, Thorgeirsson G, Stefansdottir H, et al. Several common variants modulate heart rate, PR interval and QRS duration. Nat Genet. 2010;42:117–22.CrossRefPubMed Holm H, Gudbjartsson DF, Arnar DO, Thorleifsson G, Thorgeirsson G, Stefansdottir H, et al. Several common variants modulate heart rate, PR interval and QRS duration. Nat Genet. 2010;42:117–22.CrossRefPubMed
40.
Zurück zum Zitat Smith JG, Avery CL, Evans DS, Nalls MA, Meng YA, Smith EN, et al. Impact of ancestry and common genetic variants on QT interval in African Americans. Circ Cardiovasc Genet. 2012;5:647–55.CrossRefPubMedCentralPubMed Smith JG, Avery CL, Evans DS, Nalls MA, Meng YA, Smith EN, et al. Impact of ancestry and common genetic variants on QT interval in African Americans. Circ Cardiovasc Genet. 2012;5:647–55.CrossRefPubMedCentralPubMed
41.
Zurück zum Zitat Chang K-C, Barth AS, Sasano T, Kizana E, Kashiwakura Y, Zhang Y, et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci. 2008;105:4477–82.CrossRefPubMedCentralPubMed Chang K-C, Barth AS, Sasano T, Kizana E, Kashiwakura Y, Zhang Y, et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci. 2008;105:4477–82.CrossRefPubMedCentralPubMed
42.
Zurück zum Zitat Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3:256–66.CrossRefPubMedCentralPubMed Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3:256–66.CrossRefPubMedCentralPubMed
43.
Zurück zum Zitat Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32:1065–76.CrossRefPubMedCentralPubMed Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32:1065–76.CrossRefPubMedCentralPubMed
44.
Zurück zum Zitat Arnett DK, Li N, Tang W, Rao DC, Devereux RB, Claas SA, et al. Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study. BMC Med Genet. 2009;10:43.CrossRefPubMedCentralPubMed Arnett DK, Li N, Tang W, Rao DC, Devereux RB, Claas SA, et al. Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study. BMC Med Genet. 2009;10:43.CrossRefPubMedCentralPubMed
45.
Zurück zum Zitat Del Greco MF, Pattaro C, Luchner A, Pichler I, Winkler T, Hicks AA, et al. Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster. Hum Mol Genet. 2011;20:1660–71.CrossRef Del Greco MF, Pattaro C, Luchner A, Pichler I, Winkler T, Hicks AA, et al. Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster. Hum Mol Genet. 2011;20:1660–71.CrossRef
46.
Zurück zum Zitat Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12.CrossRefPubMedCentralPubMed Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12.CrossRefPubMedCentralPubMed
47.
Zurück zum Zitat Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–7.CrossRefPubMed Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–7.CrossRefPubMed
48.
Zurück zum Zitat Trégouët D-A, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41:283–5.CrossRefPubMed Trégouët D-A, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41:283–5.CrossRefPubMed
49.••
Zurück zum Zitat Dichgans M, Malik R, König IR, Rosand J, Clarke R, Gretarsdottir S, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke J Cereb Circ. 2014;45:24–36. A valuable comparison between the common genetic determinants of stroke and coronary heart disease highlighting shared aetiological pathways.CrossRef Dichgans M, Malik R, König IR, Rosand J, Clarke R, Gretarsdottir S, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke J Cereb Circ. 2014;45:24–36. A valuable comparison between the common genetic determinants of stroke and coronary heart disease highlighting shared aetiological pathways.CrossRef
50.
Zurück zum Zitat Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng Y-C, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11:951–62.CrossRefPubMedCentralPubMed Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng Y-C, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11:951–62.CrossRefPubMedCentralPubMed
51.
Zurück zum Zitat Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RAP, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002;360:1531–9.CrossRefPubMed Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RAP, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002;360:1531–9.CrossRefPubMed
52.
Zurück zum Zitat Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–3.CrossRefPubMed Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–3.CrossRefPubMed
53.
Zurück zum Zitat Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217–24.CrossRefPubMed Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217–24.CrossRefPubMed
54.
Zurück zum Zitat Harrison SC, Kalea AZ, Holmes MV, Agu O, Humphries SE. Genomic research to identify novel pathways in the development of abdominal aortic aneurysm. Cardiol Res Pract. 2012;2012:852829.PubMedCentralPubMed Harrison SC, Kalea AZ, Holmes MV, Agu O, Humphries SE. Genomic research to identify novel pathways in the development of abdominal aortic aneurysm. Cardiol Res Pract. 2012;2012:852829.PubMedCentralPubMed
55.
Zurück zum Zitat Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries J-PPM, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010;42:692–7.CrossRefPubMedCentralPubMed Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries J-PPM, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010;42:692–7.CrossRefPubMedCentralPubMed
56.
Zurück zum Zitat Bown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas AF, et al. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet. 2011;89:619–27.CrossRefPubMedCentralPubMed Bown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas AF, et al. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet. 2011;89:619–27.CrossRefPubMedCentralPubMed
57.
Zurück zum Zitat Bradley DT, Hughes AE, Badger SA, Jones GT, Harrison SC, Wright BJ, et al. A variant in LDLR is associated with abdominal aortic aneurysm. Circ Cardiovasc Genet. 2013;6:498–504.CrossRefPubMed Bradley DT, Hughes AE, Badger SA, Jones GT, Harrison SC, Wright BJ, et al. A variant in LDLR is associated with abdominal aortic aneurysm. Circ Cardiovasc Genet. 2013;6:498–504.CrossRefPubMed
58.
Zurück zum Zitat Harrison SC, Smith AJP, Jones GT, Swerdlow DI, Rampuri R, Bown MJ, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2012;34:3707–16.CrossRefPubMedCentralPubMed Harrison SC, Smith AJP, Jones GT, Swerdlow DI, Rampuri R, Bown MJ, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2012;34:3707–16.CrossRefPubMedCentralPubMed
60.••
Zurück zum Zitat Holmes MV, Harrison S, Talmud PJ, Hingorani AD, Humphries SE. Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol. 2011;8:207–21. A comprehensive review of the underlying research and clinical utility of using genetics for predicting cardiovascular disease risk.CrossRefPubMed Holmes MV, Harrison S, Talmud PJ, Hingorani AD, Humphries SE. Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol. 2011;8:207–21. A comprehensive review of the underlying research and clinical utility of using genetics for predicting cardiovascular disease risk.CrossRefPubMed
61.
Zurück zum Zitat Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–35.CrossRefPubMedCentralPubMed Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–35.CrossRefPubMedCentralPubMed
62.
Zurück zum Zitat Ganna A, Magnusson PKE, Pedersen NL, de Faire U, Reilly M, Arnlöv J, et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013;33:2267–72.CrossRefPubMed Ganna A, Magnusson PKE, Pedersen NL, de Faire U, Reilly M, Arnlöv J, et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013;33:2267–72.CrossRefPubMed
63.
Zurück zum Zitat Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2261–6.CrossRefPubMedCentralPubMed Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2261–6.CrossRefPubMedCentralPubMed
64.
Zurück zum Zitat Hughes MF, Saarela O, Stritzke J, Kee F, Silander K, Klopp N, et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One. 2012;7:e40922.CrossRefPubMedCentralPubMed Hughes MF, Saarela O, Stritzke J, Kee F, Silander K, Klopp N, et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One. 2012;7:e40922.CrossRefPubMedCentralPubMed
65.
Zurück zum Zitat Brautbar A, Pompeii LA, Dehghan A, Ngwa JS, Nambi V, Virani SS, et al. A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis. 2012;223:421–6.CrossRefPubMedCentralPubMed Brautbar A, Pompeii LA, Dehghan A, Ngwa JS, Nambi V, Virani SS, et al. A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis. 2012;223:421–6.CrossRefPubMedCentralPubMed
66.
Zurück zum Zitat Hernesniemi JA, Seppälä I, Lyytikäinen L-P, Mononen N, Oksala N, Hutri-Kähönen N, et al. Genetic profiling using genome-wide significant coronary artery disease risk variants does not improve the prediction of subclinical atherosclerosis: the Cardiovascular Risk in Young Finns Study, the Bogalusa Heart Study and the Health 2000 Survey—a meta-analysis of three independent studies. PLoS One. 2012;7:e28931.CrossRefPubMedCentralPubMed Hernesniemi JA, Seppälä I, Lyytikäinen L-P, Mononen N, Oksala N, Hutri-Kähönen N, et al. Genetic profiling using genome-wide significant coronary artery disease risk variants does not improve the prediction of subclinical atherosclerosis: the Cardiovascular Risk in Young Finns Study, the Bogalusa Heart Study and the Health 2000 Survey—a meta-analysis of three independent studies. PLoS One. 2012;7:e28931.CrossRefPubMedCentralPubMed
67.••
Zurück zum Zitat Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393–400. A clinically focused report of a study investigating the incorporation of genetic information into coronary heart disease risk prediction.CrossRefPubMedCentralPubMed Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393–400. A clinically focused report of a study investigating the incorporation of genetic information into coronary heart disease risk prediction.CrossRefPubMedCentralPubMed
68.
Zurück zum Zitat Humphries SE, Drenos F, Ken-Dror G, Talmud PJ. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation. 2010;121:2235–48.CrossRefPubMed Humphries SE, Drenos F, Ken-Dror G, Talmud PJ. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation. 2010;121:2235–48.CrossRefPubMed
70.••
Zurück zum Zitat Davey Smith G, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22. A guide to the theoretical and practical basis of Mendelian randomisation.CrossRef Davey Smith G, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22. A guide to the theoretical and practical basis of Mendelian randomisation.CrossRef
71.••
Zurück zum Zitat Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet. 2008;123:15–33. A review of the role of Mendelian randomisation in overcoming some of the limitations of traditional epidemiology.CrossRefPubMed Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet. 2008;123:15–33. A review of the role of Mendelian randomisation in overcoming some of the limitations of traditional epidemiology.CrossRefPubMed
72.
Zurück zum Zitat Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.CrossRefPubMed Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.CrossRefPubMed
73.
Zurück zum Zitat Blood Pressure Lowering Treatment Trialists’ Collaboration, Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680.CrossRefPubMedCentral Blood Pressure Lowering Treatment Trialists’ Collaboration, Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680.CrossRefPubMedCentral
74.
Zurück zum Zitat Myung S-K, Ju W, Cho B, Oh S-W, Park SM, Koo B-K, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;346:f10.CrossRefPubMedCentralPubMed Myung S-K, Ju W, Cho B, Oh S-W, Park SM, Koo B-K, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;346:f10.CrossRefPubMedCentralPubMed
75.••
Zurück zum Zitat Hingorani A, Humphries S. Nature’s randomised trials. Lancet. 2005;366:1906–8. A concise introduction to the similarities between Mendelian randomisation and the traditional randomised controlled trial.CrossRefPubMed Hingorani A, Humphries S. Nature’s randomised trials. Lancet. 2005;366:1906–8. A concise introduction to the similarities between Mendelian randomisation and the traditional randomised controlled trial.CrossRefPubMed
76.••
Zurück zum Zitat Mendel G. Experiments in plant-hybridisation. Brunn Nat Hist Soc. 1865. Gregor Mendel’s seminal work on the inheritance of pea plant characteristics. The seminal description of the laws of what has become known as ‘Mendelian’ inheritance. These underly the Mendelian randomisation principle. Mendel G. Experiments in plant-hybridisation. Brunn Nat Hist Soc. 1865. Gregor Mendel’s seminal work on the inheritance of pea plant characteristics. The seminal description of the laws of what has become known as ‘Mendelian’ inheritance. These underly the Mendelian randomisation principle.
77.
Zurück zum Zitat Linsel-Nitschke P, Götz A, Erdmann J, Braenne I, Braund P, Hengstenberg C, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease—a Mendelian Randomisation study. PLoS One. 2008;3:e2986.CrossRefPubMedCentralPubMed Linsel-Nitschke P, Götz A, Erdmann J, Braenne I, Braund P, Hengstenberg C, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease—a Mendelian Randomisation study. PLoS One. 2008;3:e2986.CrossRefPubMedCentralPubMed
78.
Zurück zum Zitat Ference BA, Julius S, Mahajan N, Levy PD, Williams KA, Flack JM. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension. 2014;63:1182–8.CrossRefPubMed Ference BA, Julius S, Mahajan N, Levy PD, Williams KA, Flack JM. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension. 2014;63:1182–8.CrossRefPubMed
79.
Zurück zum Zitat Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2030–6.CrossRefPubMed Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2030–6.CrossRefPubMed
80.••
Zurück zum Zitat Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9. A large-scale Mendelian randomisation study implicating triglyceride-mediated aetiological pathways in the development of coronary heart disease.CrossRefPubMed Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9. A large-scale Mendelian randomisation study implicating triglyceride-mediated aetiological pathways in the development of coronary heart disease.CrossRefPubMed
81.••
Zurück zum Zitat Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2014. Report of a study using Mendelian randomisation techniques to investigate the causal contributions of major blood lipid fractions in coronary heart disease. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2014. Report of a study using Mendelian randomisation techniques to investigate the causal contributions of major blood lipid fractions in coronary heart disease.
82.••
Zurück zum Zitat Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52. An innovative Mendelian randomisation study using novel techniques to investigate further the causal contributions of plasma triglycerides in coronary disease.CrossRefPubMedCentralPubMed Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52. An innovative Mendelian randomisation study using novel techniques to investigate further the causal contributions of plasma triglycerides in coronary disease.CrossRefPubMedCentralPubMed
83.••
Zurück zum Zitat Hafiane A, Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol. 2013;2013:891403. A review discussing the controversial role of HDL cholesterol in coronary heart disease and the potential utility of pharmacological modulation of HDL-C.CrossRefPubMedCentralPubMed Hafiane A, Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol. 2013;2013:891403. A review discussing the controversial role of HDL cholesterol in coronary heart disease and the potential utility of pharmacological modulation of HDL-C.CrossRefPubMedCentralPubMed
84.
Zurück zum Zitat Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524–32.CrossRefPubMed Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524–32.CrossRefPubMed
85.
Zurück zum Zitat Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:E248–56.CrossRefPubMed Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:E248–56.CrossRefPubMed
86.••
Zurück zum Zitat Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet [Internet]. 2012 [cited 2012 Jun 2]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22607825. An important Mendelian randomisation study providing evidence that one aspect of HDL cholesterol metabolism appears not to have a causal role in the development of coronary heart disease. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet [Internet]. 2012 [cited 2012 Jun 2]; Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22607825. An important Mendelian randomisation study providing evidence that one aspect of HDL cholesterol metabolism appears not to have a causal role in the development of coronary heart disease.
87.
Zurück zum Zitat Hansson GK. Atherosclerosis—an immune disease: the Anitschkov Lecture 2007. Atherosclerosis. 2009;202:2–10.CrossRefPubMed Hansson GK. Atherosclerosis—an immune disease: the Anitschkov Lecture 2007. Atherosclerosis. 2009;202:2–10.CrossRefPubMed
88.••
Zurück zum Zitat Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. A large collaborative Mendelian randomisation study providing strong evidence against a causal role for C-reactive protein in coronary heart disease.CrossRefPubMed Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. A large collaborative Mendelian randomisation study providing strong evidence against a causal role for C-reactive protein in coronary heart disease.CrossRefPubMed
89.
Zurück zum Zitat Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst. Rev. Online. 2010;CD008331 Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst. Rev. Online. 2010;CD008331
90.••
Zurück zum Zitat Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;94:198–208. An allele score-based Mendelian randomisation study investigating the causal contribution of body mass index—a complex phenotype—in other areas of cardiometabolic disease.CrossRefPubMedCentralPubMed Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;94:198–208. An allele score-based Mendelian randomisation study investigating the causal contribution of body mass index—a complex phenotype—in other areas of cardiometabolic disease.CrossRefPubMedCentralPubMed
91.
Zurück zum Zitat Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjærg-Hansen A, Davey Smith G, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med. 2012;9:e1001212.CrossRefPubMedCentralPubMed Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjærg-Hansen A, Davey Smith G, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med. 2012;9:e1001212.CrossRefPubMedCentralPubMed
92.
Zurück zum Zitat Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.CrossRefPubMedCentralPubMed Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.CrossRefPubMedCentralPubMed
93.••
Zurück zum Zitat Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164. A landmark genetic investigation of the much-debated causal role of alcohol consumption in a range of cardiometabolic disease phenotypes.CrossRefPubMedCentralPubMed Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164. A landmark genetic investigation of the much-debated causal role of alcohol consumption in a range of cardiometabolic disease phenotypes.CrossRefPubMedCentralPubMed
94.
Zurück zum Zitat Landry Y, Gies J-P. Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol. 2008;22:1–18.CrossRefPubMed Landry Y, Gies J-P. Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol. 2008;22:1–18.CrossRefPubMed
95.
Zurück zum Zitat Nicholls SJ, Cavender MA, Kastelein JJP, Schwartz G, Waters DD, Rosenson RS, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012;26:71–5.CrossRefPubMed Nicholls SJ, Cavender MA, Kastelein JJP, Schwartz G, Waters DD, Rosenson RS, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012;26:71–5.CrossRefPubMed
96.
Zurück zum Zitat Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, et al. Secretory phospholipase A2-IIA and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2013;62(21):1966–76.CrossRefPubMedCentralPubMed Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, et al. Secretory phospholipase A2-IIA and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2013;62(21):1966–76.CrossRefPubMedCentralPubMed
97.
Zurück zum Zitat Nicholls SJ, Kastelein JJP, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311:252–62.CrossRefPubMed Nicholls SJ, Kastelein JJP, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311:252–62.CrossRefPubMed
98.
Zurück zum Zitat Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–15.CrossRefPubMed Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–15.CrossRefPubMed
99.
Zurück zum Zitat Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.CrossRefPubMed Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.CrossRefPubMed
100.••
Zurück zum Zitat Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation. 2010;121:52–62. A novel application of Mendelian randomisation for investigating adverse drug effects, providing evidence that the hypertensive effect of torcetrapib therapy was an off-target action of the drug.CrossRefPubMedCentralPubMed Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation. 2010;121:52–62. A novel application of Mendelian randomisation for investigating adverse drug effects, providing evidence that the hypertensive effect of torcetrapib therapy was an off-target action of the drug.CrossRefPubMedCentralPubMed
101.••
Zurück zum Zitat Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42. A large meta-analysis of randomised trials demonstrating the increased risk of new-onset type 2 diabetes with statin treatment.CrossRefPubMed Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42. A large meta-analysis of randomised trials demonstrating the increased risk of new-onset type 2 diabetes with statin treatment.CrossRefPubMed
102.••
Zurück zum Zitat Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64. Corroboration of the increased diabetes risk with statin therapy, showing that high-intensity statin therapy led to the greatest risk of diabetes.CrossRefPubMed Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64. Corroboration of the increased diabetes risk with statin therapy, showing that high-intensity statin therapy led to the greatest risk of diabetes.CrossRefPubMed
103.••
Zurück zum Zitat Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet [Internet]. 2014 [cited 2014 Sep 24]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673614611831. A study using data from randomised trials and Mendelian randomisation to investigate the aetiology of the increased risk of diabetes with statin therapy. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet [Internet]. 2014 [cited 2014 Sep 24]; Available from: http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S014067361461183​1. A study using data from randomised trials and Mendelian randomisation to investigate the aetiology of the increased risk of diabetes with statin therapy.
Metadaten
Titel
Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease
verfasst von
Daniel I. Swerdlow
Aroon D. Hingorani
Steve E. Humphries
Publikationsdatum
01.05.2015
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 5/2015
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0584-x

Weitere Artikel der Ausgabe 5/2015

Current Cardiology Reports 5/2015 Zur Ausgabe

Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

Interventional CMR: Clinical Applications and Future Directions

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

New Insights into the Role of Nutrition in CVD Prevention

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Role for Combination Therapy in Diabetic Dyslipidemia

Interventional Cardiology (S Rao, Section Editor)

Transradial Intervention in ST Elevation Myocardial Infarction

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.